ReNeuron Group plc (LON:RENE – Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 3.38 ($0.04) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares trading hands.
ReNeuron Group Stock Performance
The company has a market capitalization of £1.93 million, a PE ratio of -37.50 and a beta of 0.83. The firm’s fifty day simple moving average is GBX 3.38 and its 200 day simple moving average is GBX 3.38. The company has a debt-to-equity ratio of 14.25, a current ratio of 1.51 and a quick ratio of 2.02.
ReNeuron Group Company Profile
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Read More
- Five stocks we like better than ReNeuron Group
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- Are Penny Stocks a Good Fit for Your Portfolio?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
